Clinicopathological characteristics of cutaneous complications following COVID‐19 vaccination: A case series

Abstract

IntroductionSeveral vaccine‐related cutaneous adverse events occurred following the widespread use of vaccines to prevent coronavirus disease 2019 (COVID‐19). This case series reports 25 patients with de novo or accentuated dermatologic conditions after receiving the Sinopharm, Sputnik V, AstraZeneca, or BIV1‐CovIran vaccine in Iran.Methods and ResultsTwenty‐five eligible patients with a mean age of 46.80 years were investigated. The cutaneous adverse events included pityriasis rosea, zoster, viral exanthema, urticaria, bullous pemphigoid, pemphigus vulgaris, and acute generalized exanthematous pustulosis. The manifestations appeared 14.45 ± 6.98 and 20.79 ± 22.18 days following injection of the first and second doses of COVID‐19 vaccines, respectively. All patients experienced new cases of cutaneous disease other than two who developed flare‐ups of lichen planus and psoriasis.ConclusionSeveral cutaneous reactions, ranging from allergic events to skin diseases, have been reported following the injection of COVID‐19 vaccines. Focal injection‐site reactions are the most common cutaneous adverse events; however, de‐novo skin diseases and a flare‐up of preexisting cutaneous disorders have also been described. Although many cases of COVID‐19 vaccine‐related cutaneous diseases have been published, our zoster/lichen planus and AGEP cases after vaccination are interesting. A more detailed understanding of cutaneous adverse events following COVID‐19 vaccination will facilitate better diagnosis and management.

Plaque Psoriasis Exacerbation and COVID-19 Vaccination: Assessing the Characteristics of the Flare and the Exposome Parameters

“…The evidence supporting the cytokine production theory is reinforced by the protective effect of biological therapy against flares. Additionally, the utilization of biological modalities that inhibit cytokine production and action [ 59 ], including treatments, like Anakinra (anti-IL1), can be used for managing mild to severe psoriasis exacerbations [ 68 ]. However, there are no data on cytokine modifications after COVID-19 vaccinations in psoriasis patients to comprehend cytokine regulation after vaccination in this specific population, and most studies depend on findings on other COVID-19 vaccination related adverse effects, such as myocarditis [ 3 ].…”

New Onset and Exacerbation of Autoimmune Bullous Dermatosis Following COVID-19 Vaccination: A Systematic Review

“…Intravenous immunoglobulin G (IVIG) was administered in selected cases, and biologics, such as dupilumab and omalizumab, were utilized [26,34,49,55,56]. Rituximab was introduced in three cases, leading to significant improvement [51,56,63]. Most patients with pemphigus were managed with systemic corticosteroids and immunomodulators, with rituximab administered in 29% of cases [51,63,74,75,78,79,81,89].…”

“…Rituximab was introduced in three cases, leading to significant improvement [51,56,63]. Most patients with pemphigus were managed with systemic corticosteroids and immunomodulators, with rituximab administered in 29% of cases [51,63,74,75,78,79,81,89]. In one case of PVeg, intralesional injections of onabotulinum toxin, corticosteroids, and mycophenolate mofetil were used, resulting in resolution after 6 months [87].…”